Impact of the Spread of COVID-19 on Business Operations and Financial Performance
First written in FY2020. 7 of 16 entries say "Materialised", first in FY2021-Q1. Latest entry: FY2025.
The whole theme swung hardest in 2020: 102 of 175 companies on the "Worse" side.
- FY2025RestatedAnnual report
「Although the number of COVID-19-related tests performed under contract declined, revenue increased because the number of tests performed under contract other than COVID-19-related tests remained firm.」
While the number of COVID-19-related tests performed under contract continued to decline, firm trends in non-COVID-19-related testing resulted in higher Group-wide revenue. - FY2025-H1RestatedAnnual report
「Although the number of COVID-19-related tests performed under contract declined, revenue increased because the number of tests performed under contract other than COVID-19-related tests remained firm.」
While the number of COVID-19-related tests performed under contract continued to decline, firm trends in the number of other tests performed under contract resulted in a 1.8% year-on-year increase in Group-wide revenue. - FY2024MaterialisedAnnual report
「Although the number of existing tests performed under contract and revenue increased, revenue declined as the number of COVID-19-related tests fell. Profit also declined due to higher costs in addition to the decline in COVID-19-related revenue.」
The decline in COVID-19-related testing volumes and higher costs actually resulted in lower full-year revenue and profit despite an increase in the number of existing tests performed under contract and revenue. - FY2024-Q3WorsenedAnnual report
「Although the number of existing tests performed under contract and revenue increased, revenue declined because the number of COVID-19-related tests fell. Profit also declined due to higher materials costs and labour costs associated with inflation, in addition to the decline in COVID-19-related revenue.」
While the number of existing tests performed under contract and revenue increased, the decline in COVID-19-related testing volumes, together with higher materials costs and labour costs due to inflation, emerged as factors reducing profit. - FY2024-Q2MaterialisedAnnual report
「Although the number of existing tests performed under contract and revenue increased, both revenue and profit declined due to a decrease in COVID-19-related testing volumes and the impact of higher materials costs associated with inflation.」
While the number of existing tests performed under contract and revenue increased, the decline in COVID-19-related testing volumes and higher materials costs associated with inflation actually emerged as factors reducing revenue and profit. - FY2024-Q1MaterialisedAnnual report
「Although the number of existing tests contracted and revenue increased, both revenue and profit declined due to a decrease in the number of COVID-19-related tests.」
The decline in COVID-19-related testing volumes actually resulted in lower revenue and profit despite an increase in the number of existing tests performed under contract and revenue. - FY2023-Q3MaterialisedAnnual report
「Although the number of existing tests performed under contract increased, both revenue and profit declined due to the impact of lower reimbursement rates for COVID-19-related testing.」
The impact on performance of the reduction in reimbursement for COVID-19-related testing has occurred as a decline in revenue and profit alongside an increase in the number of existing tests performed under contract. - FY2023-Q2MaterialisedAnnual report
「Although the number of existing tests performed under contract increased, both revenue and profit declined due to the impact of lower reimbursement rates for COVID-19-related testing.」
The impact on performance of the reduction in reimbursement for COVID-19-related testing has actually occurred as a decline in revenue and profit alongside an increase in the number of tests performed under contract. - FY2023-Q1MaterialisedAnnual report
「Although the total number of contracted tests increased, both revenue and profit declined due to the impact of lower medical reimbursement rates for COVID-19-related tests.」
The impact on performance of the reduction in reimbursement for COVID-19-related testing actually occurred as a decline in revenue and profit alongside an increase in the number of tests performed under contract. - FY2022ReframedAnnual report
「Demand for COVID-19-related testing remains firm, while the number of tests for general medical care is also recovering. However, depending on future trends in COVID-19, the number of tests may rise or fall, which could affect the Group's business operations, financial position and operating results.」
The focus has shifted from the risk of one-way deterioration due to the spread of infection to the risk of fluctuations in testing volumes depending on infection trends, assuming continued demand for related testing and a recovery in general medical care. - FY2022-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, the Japanese economy showed some signs of recovery as economic activity gradually resumed, supported by progress in vaccinations and the effects of various policies, while the impact of COVID-19 continued for an extended period. However, infections spread again following the emergence of new variants, and the outlook remains uncertain.」
Although economic activity has resumed and shown signs of recovery with the rollout of vaccines and other measures, the outlook remains uncertain as infections have spread again due to new variants. - FY2022-Q2RestatedAnnual report
「Against this backdrop, although patient numbers in the contract clinical testing industry have remained weak due to the impact of COVID-19, the market has expanded as demand for COVID-19-related testing has grown. However, competition with other companies in the industry continues, and the business environment remains challenging.」
The disclosure continues to state that patient volumes remain weak and sales activities constrained due to COVID-19, while the market is expanding as demand for related testing grows. The impact is still occurring. - FY2022-Q1Weak patient volumes alongside expanding demand for related testingAnnual report
「Against this backdrop, in the contract clinical testing industry, patient numbers remained weak due to the impact of COVID-19, but the market expanded as demand for COVID-19-related testing grew. However, restrictions on sales activities and competition with other companies in the industry continue, leaving the business environment challenging.」
While the impact of COVID-19 continues in the form of weak patient volumes and restrictions on sales activities, the situation has shifted toward expanding demand for related testing driving market size and business performance. - FY2021-Q2MitigatedAnnual report
「In the contract clinical testing industry, patients had been avoiding medical consultations due to the spread of COVID-19, but the industry has gradually shown signs of recovery since the lifting of the state of emergency.」
Although patients have been avoiding medical consultations, the industry has gradually shown signs of recovery since the lifting of the state of emergency. However, the current fiscal year resulted in lower revenue and profit, and the disclosure does not state that the impact has been eliminated. - FY2021-Q1MaterialisedAnnual report
「The operating environment in the contract clinical testing industry remains challenging, as patients have been avoiding medical consultations due to the spread of COVID-19 and intense competition among providers continues. Against this backdrop, results for the first quarter of the current consolidated cumulative period were revenue of ¥26,109 million, down 15.3% year on year; an operating loss of ¥108 million, compared with operating profit of ¥3,179 million in the same period of the previous year; ordinary profit of ¥17 million, down 99.5% year on year; and quarterly net income attributable to owners of the parent of ¥111 million, down 94.8% year on year.」
Patients avoiding medical consultations due to the spread of COVID-19 and the deterioration in the business environment materialised as a 15.3% decline in first-quarter revenue and an operating loss of ¥108 million, among other effects on performance. - FY2020First statedAnnual report
「The outlook is expected to remain uncertain due to the impact of the spread of COVID-19. To prevent further spread of the infection, the Group has implemented thorough hygiene controls, staggered working hours and remote working, among other measures. However, if the infection spreads further, it may affect the Group's business operations, financial position and operating results.」
The risk that a further spread of COVID-19 would affect business operations, financial position and operating results was identified for the first time. In the fourth quarter, both sales and profit fell short of plan due to the impact of the infection, and the impact has already materialised.